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There is clear evidence that the global HIV epidemic is
fuelled by the war on drugs and by the criminalisation of
people who inject drugs (PWID) [1]. We also have some
evidence that the spread of hepatitis C virus (HCV) is
fuelled in the same way [2], with the resulting stigmatisa-
tion and discrimination serving as barriers to HCV care
and treatment.
Hepatitis C, like HIV, is preventable and treatable.
Unlike HIV, it is curable. Yet it remains a major cause of
morbidity and mortality, particularly in PWID [3]. There
is much higher prevalence of HCV than HIV among
PWID, especially in prisons. Global prevalence of HCV
is estimated to be about 80% among PWID, versus a
prevalence of roughly 2%–3% in general populations [4].
A staggering 90% of people who have been injecting drugs
for more than 10 years are HCV-positive, as are half of
people who have been injecting drugs for less than
10 years [2].
All health outcomes for PWID, including those asso-
ciated with hepatitis C, are far worse in countries where a
criminalisation approach is heavily favoured over the
provision of drug treatment and other health services.
Countries that respond to injecting drug use with a
balanced policy have better health outcomes [5].
The emphasis in many countries on the mass incarcera-
tion of drug users is putting prisons at the centre of the
hepatitis C epidemic. Between 16 and 41 percent of incar-
cerated people have HCV, and between 29%–43% percent
of people with HCV have been in a correction facility [6].
Despite the widespread need, treatment and care of
HCV-infected people in prisons is severely lacking.
Although HCV is the leading transmissible infection
among PWID, the medical and drug policy communities
have done little to address the HCV prevention and
treatment needs of this population. The absence of
attention to HCV in international drug policy develop-
ment [3] has contributed to HCV becoming a global
public health crisis.
The purpose of this commentary is to show how HCV
has largely been ignored in drug prevention and treatment
policies and to explain why ending the mass criminalisa-
tion of people who use drugs is a necessary component of
the public health response to hepatitis C. The following
section discusses barriers to an effective HCV response in
PWID with emphasis on the criminalisation of PWID. It is
followed by a section on overcoming barriers. The paper
then concludes by calling for a shift from criminalisation
to health promotion for PWID.
Barriers to effectively addressing the HCV-related
needs of people who inject drugs
The following all limit efforts to reduce HCV transmission
among PWID and to improve health outcomes for those
who become infected.
Lack of advocacy
In contrast to the widespread and sustained advocacy
movement that has come to characterise the global
response to HIV, efforts to represent the interests of com-
munities threatened by HCV are sporadic and fragmented.
There is insufficient public and health provider awareness
and support for preventing and controlling the disease.
This is partly related to the fact that the main transmission
route for HCV in many countries is injecting drug use,
which is associated with prejudice and criminalisation. It is
also difficult to galvanise a strong advocacy response
because the low incidence of sexual transmission of HCV
means that it is not perceived as a risk to the wider
community.
Lack of awareness in drug-using communities
Because HCV is about ten times more contagious than
HIV, there is enormous risk from sharing injecting
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equipment. Many people who inject are unaware of or
underestimate the riskiness of their own injecting beha-
viours. Many PWID who are infected with hepatitis C lack
knowledge about its long-term health consequences. What
knowledge they possess is often based on myths, outdated
information, and conflicting messages from health
providers.
Inadequate testing
Although people who use drugs and incarcerated people
are both high-risk groups, the levels of testing in these
groups are poor [1].
Lack of funding
A lack of funding for HCV prevention, treatment and
research in PWID populations can be observed in many
countries. Taking the United States as an example, at least
five million people in the United States have been infected
with HCV. That is about five times as many people as are
infected with HIV, hence a public health response to the
HCV epidemic is needed with appropriate investment in
prevention, testing, treatment and research. However the
US government has all but ignored the threat of HCV [7].
This may be linked to the difficulty of getting decision-
makers to allocate public funding to a disease associated
with injection drug use.
Treatment worldwide is costly, and the notoriously high
cost of the newest HCV drugs is likely to further amplify
concerns in this realm.
The effects of stigma on health-seeking behaviour
Negative attitudes toward PWID encourage people who
need health services to maintain hidden identities and to
conceal behaviours that put them at risk for HCV. They
may not want to acknowledge to general practitioners,
infectious disease specialists, hepatologists and other
health care providers that they have committed the
“crime” of using drugs.
Lack of health system and health professional
responsiveness to PWID
Numerous health system-related factors help to determine
whether or not PWID receive appropriate HCV services,
including knowledge and attitudes of health care workers;
the ease with which services facilitate anonymity and
discretion; and practitioners’ ability to talk authentically
and in necessary detail about someone’s behaviour and to
recognize the day-to-day contingencies that apply for
someone with a regular habit, who has inadequate means
to fund it, and little social capital to bring to bear on the
problem [8]. Furthermore, health systems often have poor
and uncoordinated HCV treatment policies for PWID,
with complex treatment pathways that are not linked to
other components of health care such as addiction
treatment.
Prejudice by treating physicians is a particular problem.
Often PWID are thought to be unworthy of receiving
treatment because they are viewed as criminals who
brought the disease on themselves. A survey of Canadian
physicians found that only 20% of HCV specialists would
consider treating HCV in PWID [9]. In England there are
huge variations in hepatitis C services offered to PWID
across the country. For example, 10 hospitals refuse
National Institute for Health and Clinical Excellence-
approved treatment to all injecting drug users; 12 hospitals
do not offer re-treatment to any patients, 55 offer it to
some patients but with varying criteria; and two hospitals
refuse treatment to anyone continuing to consume
alcohol. Around one-third of hepatitis C patients referred
to hospitals are not being offered treatment [10].
Failure to scale up harm reduction strategies
Since the 1990s, health prevention and health promotion
strategies aimed at PWID have emphasized harm reduc-
tion strategies for HIV prevention and treatment [11,12].
Such strategies have proven successful in reducing the
prevalence of HIV in settings where they have been used
[13]. Globally, however, the provision of HCV prevention
and treatment services for PWID, such as needle and
syringe programmes (NSPs), remains inadequate.
A worldwide review of coverage of NSPs in 2012 found
that although 86 countries provide NSPs and 77 countries
provide opiate substitution treatment (OST), rates of pro-
vision vary widely and do not relate to infectious disease
rates or levels of need [14]. In some countries, political
pressure is brought to bear on government officials to
discourage them from providing public services to an
“undeserving” sector of society.
In many countries where HCV is endemic, NSP avail-
ability is abysmally low. The situation is even worse for
OST, which is an effective evidence-based treatment for
drug dependence and also an effective form of HCV
prevention. Only about 40% of countries provide OST,
many inadequately [13]. In many countries, police
oppression and other forms of structural violence
further undermine efforts to deliver NSP and OST
services. Most countries do not have NSPs in prisons
and are reluctant to develop this service for prisoners
due to concerns regarding cost, violence and custodial
administrative issues [14].
Incarceration of PWID and introduction of risks to wider
prison populations
Incarceration is an independent risk factor for HCV, [15]
and many of the groups at highest risk for HCV infection
in the community remain at risk in prison. (Women in
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prison are more likely to have HCV than their male
counterparts, unlike in the general population [16].)
Many people initiate injecting drug use in prison [11].
Furthermore, custodial facilities have poor disease sur-
veillance systems.
Custodial facilities expose “at risk” young people to
injecting drugs, which they may not have accessed in their
communities. Prisoners may also have existing risk factors
for injecting, which leads to increased HCV risk, such as
psychiatric disease, while also taking on other risks in
prison, such as alienation and boredom. The culture in
prisons can lead to additional risks for HCV transmission
including tattooing, barbering, fighting, contact sports and
rape. Prison officers can discourage the adoption of pro-
tective behaviours, for example when prisoners’ requests
for bleach lead to searches and further punishment [14].
Recommendations for overcoming barriers
Although there are formidable barriers to HCV prevention
and treatment for PWID, much can be done to overcome
these barriers. Over the past few years, the seeds of HCV
advocacy groups around the world have begun to make a
difference. These include patient support groups to help
people through treatment as well as broadly focused
national organisations such as the Hepatitis C Trust in the
United Kingdom and globally the World Hepatitis
Alliance. Also, there are increasingly more examples of
accessible information about HCV circulating in PWID
communities.
However, significant progress will not be achieved
without changes at the national level in many countries.
Policy-makers and all stakeholders must become more
cognisant of the public health magnitude of the HCV
threat and the cost-effectiveness of funding HCV interven-
tions for PWID. The health costs of incarceration need to
be addressed, including showing that treating hepatitis C
in the prison population is cost-saving [17].
It is essential to fight stigma and to correct false infor-
mation. The misconception that addiction is a moral issue
must be challenged, and barriers that prevent patients
from accessing information and services must be removed.
Strategies for overcoming some key barriers are high-
lighted below.
Improve HCV testing for PWID
HCV testing has improved in some countries, notably in
European countries and in Australia, but efforts can be
better targeted at most-at-risk groups such as people who
use drugs and people who are in prison [18,19]. The orga-
nisation of services needs to be considered, since HCV
testing has improved most when it has been integrated
into existing facilities such as addiction services and gen-
eral practices.
Improve access to care and treatment for PWID
Increased funding and access for PWID will help with pre-
vention and with access to care and treatment, but this
funding needs to be used in a coordinated strategic way
[20,21], as the example of Scotland demonstrates. In 2000,
a report by the Scottish Needs Assessment Programme
(SNAP) prompted the Scottish Government to recognize
that Hepatitis C was one of the most serious and signifi-
cant public health risks, and to set about dealing with
HCV in a strategic way. The SNAP report brought
together existing initiatives to tackle hepatitis C and made
recommendations on how prevention, diagnosis and treat-
ment could be improved. An action plan was designed to
implement these recommendations, and the key messages
emerged in April 2004 [22]. The three principle objectives
were to reduce the transmission of HCV among current
PWID; to diagnose infected persons, particularly those
who are most in need of therapy; and to provide optimal
care and support for HCV-diagnosed persons. The action
plan was funded and coordinated appropriately including
a national database of diagnoses; public awareness-raising;
national needle exchange surveys; training for staff at all
levels; and models of best practice. HCV came to be
viewed as a disease that the country needed to address
rather than being marginalised as a problem for the PWID
community [22].
Provide and improve needle and syringe programmes
and opiate substitution treatment services
With some reservations, we have long known that the
availability of NSPs and OST can reduce the prevalence of
HCV [13]. Scaling up OST and high-coverage needle and
syringe programmes can reduce hepatitis C prevalence
among PWID, but reductions can be modest and require
long-term sustained intervention coverage. In high-
coverage settings, other interventions are needed to further
decrease hepatitis C prevalence. In low-coverage settings,
sustained scale-up of both interventions is needed [23].
Neither intervention protects as effectively against HCV as
it does against HIV because HCV is a more robust virus
with greater transmissibility. Prevalence of HCV is already
high in many populations by the time NSPs and OST
become available, which means that high levels of coverage
of both interventions need to be maintained on a long-
term basis, in the community as well as in prisons.
Training for people who interact with PWID
Training on HCV and harm reduction needs to be
provided to doctors, nurses and other health professionals,
and this training needs to encompass the stigma and
discrimination associated with drug use. Ancillary and
prison staff need to be trained to provide quality informa-
tion about harm reduction and HCV to at-risk groups.
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Conclusion: shifting the focus from criminalisation
to health promotion
The most important principle for improving the response
to HCV among people who inject drugs is that drug policy
and drug treatment decisions need to be based on health
objectives. When at-risk individuals come to judicial atten-
tion, they should be offered health interventions rather
than incarcerated and marginalised.
Police oppression, harmful drug policies and other forms
of structural violence need to be addressed. In parts of
Southeast Asia and the former Soviet Union, barriers
would be greatly reduced if existing laws were simply
implemented less brutally.
Building integrated drug dependence treatment systems
that bring together stakeholders from drug prevention,
health and law enforcement fields is essential. There is a
need for initiatives that aim to link these spheres, such as
the Centre for Law Enforcement and Public Health. This
web-based programme run from Australia is committed
to pursuing projects and advancing knowledge in the joint
fields of policing and other law enforcement and the many
aspects of public health [24].
One of the most important actions that must be taken is
the amendment of laws that criminalise, stigmatise and
marginalise people who use drugs. Where this approach
was tried, such as in Portugal, the number of street over-
doses fell, illicit drug use dropped, and there was a reduc-
tion in HIV prevalence among PWID [25]. Changes in
HCV trends were not monitored, but it is reasonable to
speculate that positive outcomes may have occurred in
this regard as well.
The human and societal costs of the HCV crisis must be
recognised. Governments must realise that in some ways
HCV has a similar public health impact as HIV. They
should address all of the policy issues mentioned above,
including lack of funding and uncoordinated strategies.
Providing adequate and coordinated country-wide
programmes in the community and in prisons saves
money and lives, as does providing access to treatment for
people who use drugs.
It is time to shift away from arresting and incarcerating
people for using drugs, and to instead focus on their
health – which includes acting to prevent more people
from dying unnecessarily from HCV.
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